Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017

Date: December 13, 2017
Pages: 1829
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFC23A1DAACEN
Leaflet:

Download PDF Leaflet

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 19, 103, 111, 7, 170, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 14, 34 and 15 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1752
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1766
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1770
Appendix 1779

LIST OF TABLES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Products under Development by Companies, H2 2017 (Contd.21), H2 2017
Products under Development by Companies, H2 2017 (Contd.22), H2 2017
Products under Development by Companies, H2 2017 (Contd.23), H2 2017
Products under Development by Companies, H2 2017 (Contd.24), H2 2017
Products under Development by Companies, H2 2017 (Contd.25), H2 2017
Products under Development by Companies, H2 2017 (Contd.26), H2 2017
Products under Development by Companies, H2 2017 (Contd.27), H2 2017
Products under Development by Companies, H2 2017 (Contd.28), H2 2017
Products under Development by Companies, H2 2017 (Contd.29), H2 2017
Products under Development by Companies, H2 2017 (Contd.30), H2 2017
Products under Development by Companies, H2 2017 (Contd.31), H2 2017
Products under Development by Companies, H2 2017 (Contd.32), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.10), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.11), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.10), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.11), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beactica AB, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio ASA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Co, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cell Medica Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CellCentric Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ConverGene LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CrystalGenomics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime BV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by eFFECTOR Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Co, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Emercell SAS, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem SL, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Epizyme Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Forma Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Forty Seven Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Holdings Corporation, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Glycostem Therapeutics BV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Green Cross Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GT Biopharma Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by IGF Oncology LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inflection Biosciences Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Io Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma NV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kura Oncology Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mateon Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MedImmune LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Medivir AB, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus NV, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Miltenyi Biotec GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Miragen Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mirati Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed SpA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences Srl, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NewLink Genetics Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Northern Biologics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Omeros Corp, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTartis Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmascience Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen SpA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Phylogica Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Plexxikon Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by PTC Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rafael Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Samumed LLC, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Senhwa Biosciences Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sierra Oncology Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sigma-Tau SpA, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sorrento Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Takara Bio Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TC BioPharm Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trovagene Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by VasGene Therapeutics Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vichem Chemie Research Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Viralytics Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vyriad Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xencor Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Zenith Epigenetics Ltd, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ZIOPHARM Oncology Inc, H2 2017
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 1801
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.1), H2 2017 1802
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.2), H2 2017 1803
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.3), H2 2017 1804
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.4), H2 2017 1805
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.5), H2 2017 1806
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.6), H2 2017 1807
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.7), H2 2017 1808
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.8), H2 2017 1809
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.9), H2 2017 1810
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.10), H2 2017 1811
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.11), H2 2017 1812
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.12), H2 2017 1813
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2017 (Contd.13), H2 2017 1814
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2017 1815
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2017 (Contd.1), H2 2017 1816
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2017 (Contd.2), H2 2017 1817
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2017 (Contd.3), H2 2017 1818

LIST OF FIGURES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2017 61
Number of Products under Development by Companies, H2 2017 62
Number of Products under Development by Universities/Institutes, H2 2017 78
Number of Products by Top 10 Targets, H2 2017 123
Number of Products by Stage and Top 10 Targets, H2 2017 123
Number of Products by Top 10 Mechanism of Actions, H2 2017 136
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 136
Number of Products by Routes of Administration, H2 2017 149
Number of Products by Stage and Routes of Administration, H2 2017 149
Number of Products by Top 10 Molecule Types, H2 2017 151
Number of Products by Stage and Top 10 Molecule Types, H2 2017 151

COMPANIES MENTIONED

4SC AG
AB Science SA
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affichem SA
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Altor BioScience Corp
Amgen Inc
Antigen Express Inc
Antisense Therapeutics Ltd
APIM Therapeutics AS
Aptevo Therapeutics Inc
arGEN-X BV
Ariad Pharmaceuticals Inc
Arno Therapeutics Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Asterias Biotherapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Bayer AG
BCI Pharma
Beactica AB
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
BioLineRx Ltd
BioSight Ltd
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Skip to top


Ask Your Question

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: